Antidepressant exposure during the first trimester does not increase the risk of cardiac malformations in infants

Evidence-Based Mental Health

Volumn 18, Issue 2, 2015, Pages 48-

  Payne, Jennifer L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT;

CHEMICALLY INDUCED; CONGENITAL HEART MALFORMATION; DEPRESSIVE DISORDER; FEMALE; HUMAN; MALE; PREGNANCY; PREGNANCY COMPLICATIONS;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; FEMALE; HEART DEFECTS, CONGENITAL; HUMANS; MALE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84928390229     PISSN: 13620347     EISSN: None     Source Type: Journal    
DOI: 10.1136/eb-2014-101933     Document Type: Note

References (3)

1. Louik C, Lin AE, Werler MM, et al. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007;356:2675–83.
2. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569.
3. Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007;115:2995–3014.